Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancer.

Ooki A, VandenBussche CJ, Kates M, Hahn NM, Matoso A, McConkey DJ, Bivalacqua TJ, Hoque MO.

Br J Cancer. 2018 Oct;119(8):961-970. doi: 10.1038/s41416-018-0291-7. Epub 2018 Oct 17.

PMID:
30327565
2.

A prospective Phase II study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK trial.

Iwamoto S, Ooki A, Morita S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Sudo T, Hashiguchi Y, Yabuno T, Sakamoto J, Tsuji A, Ando M, Yamaguchi K.

Cancer Med. 2018 Sep;7(9):4217-4227. doi: 10.1002/cam4.1623. Epub 2018 Jul 26.

3.

Epigenetically regulated PAX6 drives cancer cells toward a stem-like state via GLI-SOX2 signaling axis in lung adenocarcinoma.

Ooki A, Dinalankara W, Marchionni L, Tsay JJ, Goparaju C, Maleki Z, Rom WN, Pass HI, Hoque MO.

Oncogene. 2018 Nov;37(45):5967-5981. doi: 10.1038/s41388-018-0373-2. Epub 2018 Jul 6.

PMID:
29980786
4.

Arsenic promotes the COX2/PGE2-SOX2 axis to increase the malignant stemness properties of urothelial cells.

Ooki A, Begum A, Marchionni L, VandenBussche CJ, Mao S, Kates M, Hoque MO.

Int J Cancer. 2018 Jul 1;143(1):113-126. doi: 10.1002/ijc.31290. Epub 2018 Feb 14.

PMID:
29396848
5.

Targeted reversion of induced pluripotent stem cells from patients with human cleidocranial dysplasia improves bone regeneration in a rat calvarial bone defect model.

Saito A, Ooki A, Nakamura T, Onodera S, Hayashi K, Hasegawa D, Okudaira T, Watanabe K, Kato H, Onda T, Watanabe A, Kosaki K, Nishimura K, Ohtaka M, Nakanishi M, Sakamoto T, Yamaguchi A, Sueishi K, Azuma T.

Stem Cell Res Ther. 2018 Jan 22;9(1):12. doi: 10.1186/s13287-017-0754-4.

6.

Establishment of pathological quantitative method for determining undifferentiated component ratio in patients with differentiated/undifferentiated mixed-type early gastric cancer and clinical significance of this ratio.

Takeuchi H, Abe N, Hashimoto Y, Ooki A, Nagao G, Hirano K, Ookura Y, Masaki T, Mori T, Sugiyama M.

Gastric Cancer. 2018 Jul;21(4):661-671. doi: 10.1007/s10120-017-0782-x. Epub 2017 Dec 13.

PMID:
29236186
7.

YAP1 and COX2 Coordinately Regulate Urothelial Cancer Stem-like Cells.

Ooki A, Del Carmen Rodriguez Pena M, Marchionni L, Dinalankara W, Begum A, Hahn NM, VandenBussche CJ, Rasheed ZA, Mao S, Netto GJ, Sidransky D, Hoque MO.

Cancer Res. 2018 Jan 1;78(1):168-181. doi: 10.1158/0008-5472.CAN-17-0836. Epub 2017 Nov 27.

PMID:
29180467
8.

First-line bolus 5-fluorouracil plus leucovorin for peritoneally disseminated gastric cancer with massive ascites or inadequate oral intake.

Hara H, Kadowaki S, Asayama M, Ooki A, Yamada T, Yoshii T, Yamaguchi K.

Int J Clin Oncol. 2018 Apr;23(2):275-280. doi: 10.1007/s10147-017-1198-7. Epub 2017 Oct 16.

PMID:
29039072
9.

A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA.

Ooki A, Maleki Z, Tsay JJ, Goparaju C, Brait M, Turaga N, Nam HS, Rom WN, Pass HI, Sidransky D, Guerrero-Preston R, Hoque MO.

Clin Cancer Res. 2017 Nov 15;23(22):7141-7152. doi: 10.1158/1078-0432.CCR-17-1222. Epub 2017 Aug 29.

10.

Learning Advanced Medical Technology and Think about the Future, etc.

Sakai H, Hashimoto N, Shoji A, Kimoto S, Tsuruoka R, Ooki A, Kai C, Hiramatsu Y.

Nihon Hoshasen Gijutsu Gakkai Zasshi. 2017;73(7):586-596. doi: 10.6009/jjrt.2017_JSRT_73.7.586. Japanese. No abstract available.

11.

MicroRNA expression profiling of Xp11 renal cell carcinoma.

Marchionni L, Hayashi M, Guida E, Ooki A, Munari E, Jabboure FJ, Dinalankara W, Raza A, Netto GJ, Hoque MO, Argani P.

Hum Pathol. 2017 Sep;67:18-29. doi: 10.1016/j.humpath.2017.03.011. Epub 2017 Apr 12.

12.

Lymph Node Ratio as a Risk Factor for Recurrence After Adjuvant Chemotherapy in Stage III Colorectal Cancer.

Ooki A, Akagi K, Yatsuoka T, Asayama M, Hara H, Nishimura Y, Katoh H, Yamashita K, Watanabe M, Yamaguchi K.

J Gastrointest Surg. 2017 May;21(5):867-878. doi: 10.1007/s11605-017-3382-5. Epub 2017 Mar 1.

PMID:
28251467
13.

Promoter methylation of MCAM, ERα and ERβ in serum of early stage prostate cancer patients.

Brait M, Banerjee M, Maldonado L, Ooki A, Loyo M, Guida E, Izumchenko E, Mangold L, Humphreys E, Rosenbaum E, Partin A, Sidransky D, Hoque MO.

Oncotarget. 2017 Feb 28;8(9):15431-15440. doi: 10.18632/oncotarget.14873.

14.

Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy.

Yamaguchi K, Ando M, Ooki A, Beier F, Guenther S, von Hohnhorst P, Van Cutsem E.

Clin Colorectal Cancer. 2017 Jun;16(2):e29-e37. doi: 10.1016/j.clcc.2016.07.017. Epub 2016 Aug 9.

15.

The conservative behavior of dissolved organic carbon in surface waters of the southern Chukchi Sea, Arctic Ocean, during early summer.

Tanaka K, Takesue N, Nishioka J, Kondo Y, Ooki A, Kuma K, Hirawake T, Yamashita Y.

Sci Rep. 2016 Sep 23;6:34123. doi: 10.1038/srep34123.

16.

Genomic gain of the PRL-3 gene may represent poor prognosis of primary colorectal cancer, and associate with liver metastasis.

Nakayama N, Yamashita K, Tanaka T, Kawamata H, Ooki A, Sato T, Nakamura T, Watanabe M.

Clin Exp Metastasis. 2016 Jan;33(1):3-13. doi: 10.1007/s10585-015-9749-7. Epub 2015 Nov 12.

PMID:
26563151
17.

Discrepancies between the K-ras mutational status of primary colorectal cancers and corresponding liver metastases are found in codon 13.

Kawamata H, Yamashita K, Kojo K, Ushiku H, Ooki A, Watanabe M.

Genomics. 2015 Aug;106(2):71-5. doi: 10.1016/j.ygeno.2015.05.007. Epub 2015 May 28.

18.

Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.

Fuse N, Kuboki Y, Kuwata T, Nishina T, Kadowaki S, Shinozaki E, Machida N, Yuki S, Ooki A, Kajiura S, Kimura T, Yamanaka T, Shitara K, Nagatsuma AK, Yoshino T, Ochiai A, Ohtsu A.

Gastric Cancer. 2016 Jan;19(1):183-91. doi: 10.1007/s10120-015-0471-6. Epub 2015 Feb 15.

PMID:
25682441
19.

Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer.

Kadowaki S, Kakuta M, Takahashi S, Takahashi A, Arai Y, Nishimura Y, Yatsuoka T, Ooki A, Yamaguchi K, Matsuo K, Muro K, Akagi K.

World J Gastroenterol. 2015 Jan 28;21(4):1275-83. doi: 10.3748/wjg.v21.i4.1275.

20.

Laterally spreading iron, humic-like dissolved organic matter and nutrients in cold, dense subsurface water of the Arctic Ocean.

Hioki N, Kuma K, Morita Y, Sasayama R, Ooki A, Kondo Y, Obata H, Nishioka J, Yamashita Y, Nishino S, Kikuchi T, Aoyama M.

Sci Rep. 2014 Oct 27;4:6775. doi: 10.1038/srep06775.

21.

Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer.

Ooki A, Akagi K, Yatsuoka T, Asayama M, Hara H, Takahashi A, Kakuta M, Nishimura Y, Yamaguchi K.

J Surg Oncol. 2014 Dec;110(8):982-8. doi: 10.1002/jso.23755. Epub 2014 Aug 22.

PMID:
25154726
22.

Inverse effect of mucinous component on survival in stage III colorectal cancer.

Ooki A, Akagi K, Yatsuoka T, Asayama M, Hara H, Yamamoto G, Nishimura Y, Yamaguchi K.

J Surg Oncol. 2014 Dec;110(7):851-7. doi: 10.1002/jso.23742. Epub 2014 Aug 11.

PMID:
25111953
23.
24.

Everolimus dramatically improves glycemic control in unresectable metastatic insulinoma: a case report.

Asayama M, Yamada-Murano T, Hara H, Ooki A, Kurosumi M, Yamaguchi K.

Jpn J Clin Oncol. 2014 Feb;44(2):186-90. doi: 10.1093/jjco/hyt193. Epub 2013 Dec 22.

PMID:
24367043
25.

[Therapeutic strategy for recurrent gastric cancer and efforts aimed at finding a cure].

Asayama M, Yamada-Murano T, Hara H, Ooki A, Yoshii T, Yamaguchi K.

Gan To Kagaku Ryoho. 2013 Aug;40(8):976-80. Japanese.

PMID:
23986038
26.

DNA damage-inducible gene, reprimo functions as a tumor suppressor and is suppressed by promoter methylation in gastric cancer.

Ooki A, Yamashita K, Yamaguchi K, Mondal A, Nishimiya H, Watanabe M.

Mol Cancer Res. 2013 Nov;11(11):1362-74. doi: 10.1158/1541-7786.MCR-13-0091. Epub 2013 Aug 27.

27.

Recent developments in gastric endoscopic submucosal dissection: towards the era of endoscopic resection of layers deeper than the submucosa.

Abe N, Takeuchi H, Ooki A, Nagao G, Masaki T, Mori T, Sugiyama M.

Dig Endosc. 2013 Mar;25 Suppl 1:64-70. doi: 10.1111/j.1443-1661.2012.01387.x. Epub 2013 Jan 24. Review.

PMID:
23368096
28.

Cancer specific promoter CpG Islands hypermethylation of HOP homeobox (HOPX) gene and its potential tumor suppressive role in pancreatic carcinogenesis.

Waraya M, Yamashita K, Katoh H, Ooki A, Kawamata H, Nishimiya H, Nakamura K, Ema A, Watanabe M.

BMC Cancer. 2012 Sep 7;12:397. doi: 10.1186/1471-2407-12-397.

29.

Epigenetic silencing of HOPX promotes cancer progression in colorectal cancer.

Katoh H, Yamashita K, Waraya M, Margalit O, Ooki A, Tamaki H, Sakagami H, Kokubo K, Sidransky D, Watanabe M.

Neoplasia. 2012 Jul;14(7):559-71.

30.

Laparoscopic resection of a gastrointestinal stromal tumor of the rectum after treatment with imatinib mesylate: report of a case.

Nakamura T, Mitomi H, Onozato W, Sato T, Ikeda A, Naito M, Ogura N, Kamata H, Ooki A, Watanabe M.

Surg Today. 2012 Nov;42(11):1096-9.

PMID:
22294424
31.

Short- and long-term outcomes of laparoscopic surgery in patients with pathological stage II and III colon cancer.

Nakamura T, Mitomi H, Onozato W, Sato T, Ikeda A, Naito M, Ogura N, Kamata H, Ooki A, Watanabe M.

Hepatogastroenterology. 2011 Nov-Dec;58(112):1947-50. doi: 10.5754/hge11196.

PMID:
22024064
32.

Oncological outcomes of laparoscopic surgery in elderly patients with colon cancer: a comparison of patients 64 years or younger with those 75 years or older.

Nakamura T, Mitomi H, Onozato W, Sato T, Ikeda A, Naito M, Ogura N, Kamata H, Ooki A, Watanabe M.

Hepatogastroenterology. 2011 Jul-Aug;58(109):1200-4. doi: 10.5754/hge11086.

PMID:
21937378
33.

Therapeutic potential of PRL-3 targeting and clinical significance of PRL-3 genomic amplification in gastric cancer.

Ooki A, Yamashita K, Kikuchi S, Sakuramoto S, Katada N, Waraya M, Kawamata H, Nishimiya H, Nakamura K, Watanabe M.

BMC Cancer. 2011 Apr 6;11:122. doi: 10.1186/1471-2407-11-122.

34.

Potential utility of HOP homeobox gene promoter methylation as a marker of tumor aggressiveness in gastric cancer.

Ooki A, Yamashita K, Kikuchi S, Sakuramoto S, Katada N, Kokubo K, Kobayashi H, Kim MS, Sidransky D, Watanabe M.

Oncogene. 2010 Jun 3;29(22):3263-75. doi: 10.1038/onc.2010.76. Epub 2010 Mar 15.

PMID:
20228841
35.

Phosphatase of regenerating liver-3 as a convergent therapeutic target for lymph node metastasis in esophageal squamous cell carcinoma.

Ooki A, Yamashita K, Kikuchi S, Sakuramoto S, Katada N, Watanabe M.

Int J Cancer. 2010 Aug 1;127(3):543-54. doi: 10.1002/ijc.25082.

36.

Equilibrator inlet-proton transfer reaction-mass spectrometry (EI-PTR-MS) for sensitive, high-resolution measurement of dimethyl sulfide dissolved in seawater.

Kameyama S, Tanimoto H, Inomata S, Tsunogai U, Ooki A, Yokouchi Y, Takeda S, Obata H, Uematsu M.

Anal Chem. 2009 Nov 1;81(21):9021-6. doi: 10.1021/ac901630h.

PMID:
19791769
37.

Phosphatase of regenerating liver-3 as a prognostic biomarker in histologically node-negative gastric cancer.

Ooki A, Yamashita K, Kikuchi S, Sakuramoto S, Katada N, Watanabe M.

Oncol Rep. 2009 Jun;21(6):1467-75.

PMID:
19424625
38.

Clinical significance of total gastrectomy for proximal gastric cancer.

Ooki A, Yamashita K, Kikuchi S, Sakuramoto S, Katada N, Hutawatari N, Watanabe M.

Anticancer Res. 2008 Sep-Oct;28(5B):2875-83.

39.
40.

Lymph node metastasis density (ND)-factor association with malignant degree and ND40 as "non-curative factor" in gastric cancer.

Yamashita K, Ooki A, Sakuramoto S, Kikuchi S, Katada N, Kobayashi N, Watanabe M.

Anticancer Res. 2008 Jan-Feb;28(1B):435-41.

41.

Lymph node metastasis density and growth pattern as independent prognostic factors in advanced esophageal squamous cell carcinoma.

Ooki A, Yamashita K, Kobayashi N, Katada N, Sakuramoto S, Kikuchi S, Watanabe M.

World J Surg. 2007 Nov;31(11):2184-91. Epub 2007 Aug 24.

PMID:
17721721

Supplemental Content

Support Center